Literature DB >> 24146211

Tomatoes, lysophosphatidic acid, and the small intestine: new pieces in the puzzle of apolipoprotein mimetic peptides?

A T Remaley1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24146211      PMCID： PMC3826671          DOI： 10.1194/jlr.E045054

Source DB:  PubMed          Journal:  J Lipid Res        ISSN： 0022-2275            Impact factor:   5.922


× No keyword cloud information.
  23 in total

1.  Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide.

Authors:  G Datta; M Chaddha; S Hama; M Navab; A M Fogelman; D W Garber; V K Mishra; R M Epand; R F Epand; S Lund-Katz; M C Phillips; J P Segrest; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2001-07       Impact factor: 5.922

2.  Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides.

Authors:  Amar A Sethi; John A Stonik; Fairwell Thomas; Steve J Demosky; Marcelo Amar; Edward Neufeld; H Bryan Brewer; W Sean Davidson; Wilissa D'Souza; Dmitri Sviridov; Alan T Remaley
Journal:  J Biol Chem       Date:  2008-09-19       Impact factor: 5.157

Review 3.  Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis.

Authors:  Amar A Sethi; Marcelo Amar; Robert D Shamburek; Alan T Remaley
Journal:  Curr Opin Investig Drugs       Date:  2007-03

4.  The C-terminal lipid-binding domain of apolipoprotein E is a highly efficient mediator of ABCA1-dependent cholesterol efflux that promotes the assembly of high-density lipoproteins.

Authors:  Charulatha Vedhachalam; Vasanthy Narayanaswami; Nicole Neto; Trudy M Forte; Michael C Phillips; Sissel Lund-Katz; John K Bielicki
Journal:  Biochemistry       Date:  2007-02-17       Impact factor: 3.162

5.  Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine.

Authors:  G M Anantharamaiah; J L Jones; C G Brouillette; C F Schmidt; B H Chung; T A Hughes; A S Bhown; J P Segrest
Journal:  J Biol Chem       Date:  1985-08-25       Impact factor: 5.157

Review 6.  Two pathways for lysophosphatidic acid production.

Authors:  Junken Aoki; Asuka Inoue; Shinichi Okudaira
Journal:  Biochim Biophys Acta       Date:  2008-06-24

7.  Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I.

Authors:  Brian J Van Lenten; Alan C Wagner; Chun-Ling Jung; Piotr Ruchala; Alan J Waring; Robert I Lehrer; Andrew D Watson; Susan Hama; Mohamad Navab; G M Anantharamaiah; Alan M Fogelman
Journal:  J Lipid Res       Date:  2008-07-11       Impact factor: 5.922

8.  A novel approach to oral apoA-I mimetic therapy.

Authors:  Arnab Chattopadhyay; Mohamad Navab; Greg Hough; Feng Gao; David Meriwether; Victor Grijalva; James R Springstead; Mayakonda N Palgnachari; Ryan Namiri-Kalantari; Feng Su; Brian J Van Lenten; Alan C Wagner; G M Anantharamaiah; Robin Farias-Eisner; Robin Farias-Eisener; Srinivasa T Reddy; Alan M Fogelman
Journal:  J Lipid Res       Date:  2013-02-02       Impact factor: 5.922

Review 9.  HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications.

Authors:  Alan T Remaley; Marcelo Amar; Dmitri Sviridov
Journal:  Expert Rev Cardiovasc Ther       Date:  2008-10

10.  Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients.

Authors:  Leanne T Bloedon; Richard Dunbar; Danielle Duffy; Paula Pinell-Salles; Robert Norris; Bruce J DeGroot; Rajesh Movva; Mohamad Navab; Alan M Fogelman; Daniel J Rader
Journal:  J Lipid Res       Date:  2008-03-06       Impact factor: 5.922
View more
  7 in total

1.  Source and role of intestinally derived lysophosphatidic acid in dyslipidemia and atherosclerosis.

Authors:  Mohamad Navab; Arnab Chattopadhyay; Greg Hough; David Meriwether; Spencer I Fogelman; Alan C Wagner; Victor Grijalva; Feng Su; G M Anantharamaiah; Lin H Hwang; Kym F Faull; Srinivasa T Reddy; Alan M Fogelman
Journal:  J Lipid Res       Date:  2015-02-02       Impact factor: 5.922

Review 2.  Novel concepts in HDL pharmacology.

Authors:  Alan T Remaley; Giuseppe D Norata; Alberico L Catapano
Journal:  Cardiovasc Res       Date:  2014-06-20       Impact factor: 10.787

3.  Tg6F ameliorates the increase in oxidized phospholipids in the jejunum of mice fed unsaturated LysoPC or WD.

Authors:  Arnab Chattopadhyay; Mohamad Navab; Greg Hough; Victor Grijalva; Pallavi Mukherjee; Hannah R Fogelman; Lin H Hwang; Kym F Faull; Aldons J Lusis; Srinivasa T Reddy; Alan M Fogelman
Journal:  J Lipid Res       Date:  2016-03-09       Impact factor: 5.922

4.  Intravenous toxicity and toxicokinetics of an HDL mimetic, Fx-5A peptide complex, in cynomolgus monkeys.

Authors:  Mohammed Bourdi; Marcelo Amar; Alan T Remaley; Pramod S Terse
Journal:  Regul Toxicol Pharmacol       Date:  2018-10-22       Impact factor: 3.271

Review 5.  Apolipoprotein A-I mimetics.

Authors:  Srinivasa T Reddy; Mohamad Navab; Gattadahalli M Anantharamaiah; Alan M Fogelman
Journal:  Curr Opin Lipidol       Date:  2014-08       Impact factor: 4.776

Review 6.  Fat of the Gut: Epithelial Phospholipids in Inflammatory Bowel Diseases.

Authors:  Lidiya V Boldyreva; Maryana V Morozova; Snezhanna S Saydakova; Elena N Kozhevnikova
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

Review 7.  Apolipoprotein Mimetic Peptides: Potential New Therapies for Cardiovascular Diseases.

Authors:  Anna Wolska; Mart Reimund; Denis O Sviridov; Marcelo J Amar; Alan T Remaley
Journal:  Cells       Date:  2021-03-08       Impact factor: 6.600
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.